Editor’s Note: Find the latest news about COVID-19 and in the Medscape Coronavirus Resource Center.
Evusheld (AstraZeneca), a drug used to save SARS-CoV-2 infection in high-risk patients, has problems, namely that the source of life-saving drugs outweighs demand.
At least 7 million immunocompromised people could benefit, as could many others undergoing cancer treatment, getting a transplant, or allergic to COVID-19 vaccines. The drug contains laboratory-produced antibodies that oppose SARS-CoV-2 and is helping the framework itself. It can reduce the chances of it becoming inflamed by up to 77%, according to the U. S. Food and Drug Administration (FDA).
And it’s flexible for eligible patients (though there would possibly be refundable administrative fees in some cases).
Despite all those life-saving benefits, less than 25% of the available doses were used.
To meet demand, Biden’s management received 1. 7 million doses of the drug, which obtained emergency use authorization from the FDA in December 2021. However, as of July 25, 793,348 doses have been ordered through the management sites and only 398,181 doses have been delivered. reported as used, a spokesperson for the fitness and human division (HHS) told Medscape Medical News.
Each week, a certain amount of doses from the 1. 7 million dose reserve is sent to state and territorial health services. States have not implemented their full allocation, the spokesman said Thursday.
Now, HHS and AstraZeneca have taken a number of steps to raise awareness about the drug.
On Wednesday, HHS announced that individual providers and small care sites that recently obtain Evusheld through the federal distribution procedure through the HHS Healthcare Partner Order Portal can now order up to 3 drug remedies for patients. These can be ordered online.
Health care providers can use HHS’s COVID-19 therapeutic locator for Evusheld in their area.
AstraZeneca has introduced a novelty with educational fabrics and says it works heavily with patient teams and professionals to inform patients and healthcare providers.
A direct-to-consumer ad featured on June 22 and broadcast in the United States online and on television (Yahoo, Fox, CBS Sports, MSN, ESPN) and will be amplified on social and virtual media through the end of the year, an AstraZeneca spokesperson said. Medscape Medical News.
AstraZeneca has set up a toll-free provider number: 1-833-EVUSHLD.
Evusheld includes two monoclonal antibodies, tixagevimab and cilgavimab. The drug is given in two consecutive intramuscular injections on a singles scale in a doctor’s office, infusion center, or other gym. The antibodies bind to the sars-CoV-2 spike protein and save it from the virus entering and infecting human cells. Its use is allowed in young people and adults over 12 years of age and older weighing at least 88 pounds.
Studies have shown that the drug decreases the threat of contracting COVID-19 up to 6 months after administration. The FDA recommends repeating the trial both one and 6 months with doses of three hundred mg of monoclonal antibody. In clinical trials, Evusheld reduced the incidence of symptomatic COVID-19 disease by 77% compared to placebo.
Doctors monitor patients for one hour after treatment with Evusheld for allergic reactions. Other imaginable side effects come with cardiac events, but they are not common.
Doctors, and patients, from the U. S. even the UK and beyond are wondering why the drug is underutilized while praising recent efforts to expand and raise awareness.
The U. S. federal government The U. S. food and drug administration may have underestimated the amount of communication needed to raise awareness about the drug and its applications, said infectious disease specialist William Schaffner, MD, a professor of preventive medicine at Vanderbilt University School of Medicine, Nashville.
“HHS has made a primary educational effort to publicize it,” he told Medscape Medical News.
Many doctors who want to be informed, such as transplanters and rheumatologists, are outdoors in the typical cycle of public communication about fitness, he said.
Eric Topol, MD, director of the Scripps Research Transational Institute and editor-in-chief of Medscape, took to social media to lament the lack of awareness.
Another infectious disease expert agrees. ” In my experience, Evusheld’s wisdom is low in many patients as well as many providers,” said Amesh Adalja, MD, principal investigator at the Johns Hopkins Center for Health Security in Baltimore.
“Initially, drug stocks were scarce, and some hospital systems staggered eligibility based on degrees of immunosuppression and only proactively addressed for treatment at the highest immunocompromised.
“Also, first of all, many hospitals in the network never applied for Evusheld; possibly they would have been expelled by educational centers that treat many more immunocompromised patients and possibly would not be a priority lately,” Adalja told Medscape Medical News. “Therefore, many immunocompromised patients deserve to seek remedy in educational medical centers where the drug is most likely to be available. “
For more information, Medscape on Facebook, Twitter, Instagram and YouTube.
Credits:
Main image: AstraZeneca
Medscape © Medical News 2022
You have already decided on My Alerts
Click on the subject line below to receive emails when new items are available.